Trifarotene, sold under the brand name Aklief, is a medication for the topical treatment of acne vulgaris.[6][8] It is a retinoid;[6][9] specifically, a fourth-generation selective retinoic acid receptor (RAR)-γ agonist.[10]
Trifarotene was granted orphan drug designation for the treatment of congenital ichthyosis by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).[11][12] It was approved for medical use in the United States in October 2019.[8][13][14] In December 2019, its labelling and package leaflet text received a decentralised approval for 16 European countries.[7]
In the United States, trifarotene is indicated for the topical treatment of acne vulgaris in people nine years of age and older.[6] In both Canada and Australia, it is indicated for the topical treatment of acne vulgaris of the face and/or the trunk in people twelve years of age and older.[1][2][3]
Most adverse effects of topical trifarotene for the treatment of acne are at the location side and transient, such as application site irritation, allergic dermatitis, skin irritation and sunburn.[15] Even though systemic absorption is very low,[16] use of trifarotene is still contraindicated during pregnancy[17] because of the known risk of teratogenicity of the overall class of drugs trifarotene belongs to, retinoids.
Trifarotene was approved for medical use in the United States in October 2019,[14] in Canada in November 2019,[3] and in Australia in January 2021.[1][2]
This dermatologic drug article is a stub. You can help Wikipedia by expanding it.